177lu-psma-617,cabazitaxel
novartis
['crpc', 'pacap study', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', '#pacap', 'cabazitaxel']
activity of lu-psma and determinants of outcomes in patients with #mcrpc previously treated with cabazitaxel: the #pacap study. presented by . #gu23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology